M. Alexander Shaw
M. Alexander Shaw (Alex), CEO, has spent the past 15 years growing Nuventra Pharma Sciences from a two-person boutique pharmacokinetic consulting shop into a 125-person full-service drug development consulting group with $22M in annual revenue and $2M in annual profit. During that time, he advised over 100 clients in the pharmacokinetic and clinical pharmacology aspects of drug approval. He was also responsible for all operational aspects of the company, including finance, human resources, business analytics, and project management. After successfully exiting Nuventra via sale of the company, Alex looks forward to applying his drug development expertise along with his experience in running a business to helping Prolifagen develop a robust therapeutic portfolio.